Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardonilimab plus lenvatinib in renal cell carcinoma
ChiCTR2400090483Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab and lenvatinib in renal cell carcinoma (RCC), clear cell renal cell carcinoma (ccRCC) and chromophobe renal cell carcinoma (chRCC) (2 cohorts), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
cadonilimablenvatinib
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)chromophobe renal cell carcinoma (chRCC)
Beyond the preview
Go deeper on ChiCTR2400090483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090483.